免疫生物学ジャーナル

p53 Antibodies as a Diagnostic Marker for Cancer: Results from a Meta-Analysis

Abstract

Navid Sobhani*, Daniele Generali, Giandomenico Roviello, Alberto D'Angelo and Raheleh Roudi

P53 is an unequivocal tumor suppressor altered in most sporadic human cancers. The loss of p53 initiates progression of malignancies and it is characterized by more malignant factors, such as an increase of the risk of cancer cells to become more invasive and potentially metastatic, genomic instability and poor cellular differentiation. Many studies have evaluated the clinical stability of serum p53 antibodies (s-p53-Abs).